Arcutis Biotherapeutics, Inc. ARQT
32.00 USD +0.74 (+2.37%)
At closeNov 4, 2026, 7:35 AM EST
32.50 +0.50 +1.56%
Pre-market · Nov 4, 7:35 AM ET
31.27 Day range 32.39
19.30 52-week range 33.30
- YTD
- +10.19%
- 1 year
- +33.28%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 39.13 +22.3% upside
Now 32.00
- Target (low)
- 34.00
- Target (mean)
- 39.13
- Target (high)
- 48.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy2
- Buy5
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 7
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.16833 | 0.10 – 0.20 | 0.06 | +180.6% | 142.59M | +43.7% | 6 |
| Next quarter | 0.23167 | 0.03 – 0.39 | 0.13 | +78.2% | 160.67M | +24.1% | 6 |
| Current year | 0.425 | 0.20 – 0.62 | -0.13 | +426.9% | 538.56M | +43.2% | 6 |
| Next year | 1.34 | 0.80 – 2.08 | 0.425 | +214.9% | 695.69M | +29.2% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | Guggenheim | Maintained | Buy | Buy |
| Oct 15, 2026 | Cantor Fitzgerald | Initiated | — | Overweight |
| Aug 6, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 6, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 6, 2026 | Needham | Maintained | Buy | Buy |
| May 7, 2026 | Needham | Reiterated | Buy | Buy |
| Mar 2, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Feb 27, 2026 | Guggenheim | Maintained | Buy | Buy |
| Feb 26, 2026 | TD Cowen | Maintained | Buy | Buy |
| Feb 26, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 26, 2026 | Needham | Maintained | Buy | Buy |
| Jan 26, 2026 | Needham | Maintained | Buy | Buy |
| Nov 28, 2025 | Mizuho | Maintained | Outperform | Outperform |
| Oct 30, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Oct 28, 2025 | Needham | Maintained | Buy | Buy |
| Aug 7, 2025 | Needham | Maintained | Buy | Buy |
| Jul 25, 2025 | Goldman Sachs | Initiated | — | Neutral |
| May 23, 2025 | Needham | Reiterated | Buy | Buy |
| Apr 9, 2025 | Needham | Reiterated | Buy | Buy |
| Apr 3, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Apr 3, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 3, 2025 | Needham | Reiterated | Buy | Buy |
| Mar 11, 2025 | Jefferies | Maintained | Buy | Buy |
| Feb 27, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Feb 26, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 26, 2025 | Mizuho | Maintained | Outperform | Outperform |
| Feb 26, 2025 | Needham | Reiterated | Buy | Buy |
| Feb 24, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Feb 10, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Jan 13, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |